Skip to main content
Erschienen in: Japanese Journal of Radiology 5/2013

01.05.2013 | Pictorial Essay

18F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay

verfasst von: Kazuhiro Kitajima, Atsushi Kono, Jyunya Konishi, Yuko Suenaga, Satoru Takahashi, Kazuro Sugimura

Erschienen in: Japanese Journal of Radiology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

A variety of different tumors can arise from any of the tissues present in the retroperitoneum, and they exhibit a wide range of pathologic types. Although computed tomography (CT) and magnetic resonance imaging (MRI) can demonstrate important characteristics of these tumors, diagnosis is often challenging for radiologists. The purpose of this pictorial essay is to review 18F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) features of different kinds of benign and malignant retroperitoneal tumors in comparison with CT or MRI findings alone and to become familiar with the wide variety of imaging characteristics.
Literatur
1.
Zurück zum Zitat Lane RH, Stephens DH, Reiman HM. Primary retroperitoneal neoplasms: CT findings in 90 cases with clinical and pathologic correlation. AJR Am J Roentgenol. 1989;152:83–9.PubMedCrossRef Lane RH, Stephens DH, Reiman HM. Primary retroperitoneal neoplasms: CT findings in 90 cases with clinical and pathologic correlation. AJR Am J Roentgenol. 1989;152:83–9.PubMedCrossRef
2.
Zurück zum Zitat Tateishi U, Terauchi T, Inoue T, Tobinai K. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT. Abdom Imaging. 2010;35:232–40.PubMedCrossRef Tateishi U, Terauchi T, Inoue T, Tobinai K. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT. Abdom Imaging. 2010;35:232–40.PubMedCrossRef
3.
Zurück zum Zitat Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50:21–30.CrossRef Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50:21–30.CrossRef
5.
Zurück zum Zitat Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, et al. Assessment of soft tissue lesions suspicious for liposarcoma by 18F-deoxy-glucose (FDG) positron emission tomography (PET). Anticancer Res. 2001;21:3609–14.PubMed Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, et al. Assessment of soft tissue lesions suspicious for liposarcoma by 18F-deoxy-glucose (FDG) positron emission tomography (PET). Anticancer Res. 2001;21:3609–14.PubMed
6.
Zurück zum Zitat Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006;33:1290–5.PubMedCrossRef Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006;33:1290–5.PubMedCrossRef
7.
Zurück zum Zitat Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT of uterine tumors. AJR Am J Roentgenol. 2010;195:737–43.PubMedCrossRef Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT of uterine tumors. AJR Am J Roentgenol. 2010;195:737–43.PubMedCrossRef
8.
Zurück zum Zitat Yamane T, Takaoka A, Kita M, Imai Y, Senda M. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med. 2012;26:478–84. Yamane T, Takaoka A, Kita M, Imai Y, Senda M. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med. 2012;26:478–84.
9.
Zurück zum Zitat Tsujikawa T, Yoshida Y, Mori T, et al. Uterine tumors: pathophysiologic imaging with 16α-[18F]fluoro-17β-estradiol and 18F-fluorodeoxyglucose PET—initial experience. Radiology. 2008;248:599–605.PubMedCrossRef Tsujikawa T, Yoshida Y, Mori T, et al. Uterine tumors: pathophysiologic imaging with 16α-[18F]fluoro-17β-estradiol and 18F-fluorodeoxyglucose PET—initial experience. Radiology. 2008;248:599–605.PubMedCrossRef
10.
Zurück zum Zitat Ito K, Masuda-Miyata Y, Wada S, Morooka M, Yamasawa K, Hashimoto M, et al. F-18 FDG PET/CT imaging of bulky myxofibrosarcoma in chest wall. Clin Nucl Med. 2011;36:212–3. Ito K, Masuda-Miyata Y, Wada S, Morooka M, Yamasawa K, Hashimoto M, et al. F-18 FDG PET/CT imaging of bulky myxofibrosarcoma in chest wall. Clin Nucl Med. 2011;36:212–3.
11.
Zurück zum Zitat Hwang SS, Park SY, Park YH. The CT and F-FDG PET/CT appearance of primary renal malignant fibrous histiocytoma. J Med Imaging Radiat Oncol. 2010;54:365–7.PubMedCrossRef Hwang SS, Park SY, Park YH. The CT and F-FDG PET/CT appearance of primary renal malignant fibrous histiocytoma. J Med Imaging Radiat Oncol. 2010;54:365–7.PubMedCrossRef
12.
Zurück zum Zitat Berrebi O, Steiner C. keller A, Rougemont AL, Ratib O. F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med. 2008;33:469–71.PubMedCrossRef Berrebi O, Steiner C. keller A, Rougemont AL, Ratib O. F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med. 2008;33:469–71.PubMedCrossRef
13.
Zurück zum Zitat De Giorgi U, Pupi A, Fiorentini G, Rosti G, Marangolo M. FDG-PET in the management of germ cell tumor. Ann Oncol. 2005;16:90–4.CrossRef De Giorgi U, Pupi A, Fiorentini G, Rosti G, Marangolo M. FDG-PET in the management of germ cell tumor. Ann Oncol. 2005;16:90–4.CrossRef
14.
Zurück zum Zitat Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270–4.PubMedCrossRef Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270–4.PubMedCrossRef
15.
Zurück zum Zitat Park JW, Cho CH, Jeong D, Chae HD. Role of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer. 2011;11:173–9.PubMedCrossRef Park JW, Cho CH, Jeong D, Chae HD. Role of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer. 2011;11:173–9.PubMedCrossRef
16.
Zurück zum Zitat Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.PubMed Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.PubMed
17.
Zurück zum Zitat Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF. Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR. 2004;182:971–4.PubMedCrossRef Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF. Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR. 2004;182:971–4.PubMedCrossRef
18.
Zurück zum Zitat Hamada K, Tomita Y, Qiu Y, Tomoeda M, Ueda T, Tamai N, et al. 18F-FDG PET analysis of schwannoma: increase of SUVmax in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009;38:261–6.PubMedCrossRef Hamada K, Tomita Y, Qiu Y, Tomoeda M, Ueda T, Tamai N, et al. 18F-FDG PET analysis of schwannoma: increase of SUVmax in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009;38:261–6.PubMedCrossRef
19.
Zurück zum Zitat Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[Fulorine-18]fluoro-2-deoxy-d-glucose PET. Radiology. 1999;212:35–41.PubMed Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[Fulorine-18]fluoro-2-deoxy-d-glucose PET. Radiology. 1999;212:35–41.PubMed
20.
Zurück zum Zitat Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG activity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711–7.PubMedCrossRef Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG activity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711–7.PubMedCrossRef
21.
Zurück zum Zitat Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, et al. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med. 2006;20:357–60.PubMedCrossRef Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, et al. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med. 2006;20:357–60.PubMedCrossRef
Metadaten
Titel
18F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay
verfasst von
Kazuhiro Kitajima
Atsushi Kono
Jyunya Konishi
Yuko Suenaga
Satoru Takahashi
Kazuro Sugimura
Publikationsdatum
01.05.2013
Verlag
Springer Japan
Erschienen in
Japanese Journal of Radiology / Ausgabe 5/2013
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-013-0192-x

Weitere Artikel der Ausgabe 5/2013

Japanese Journal of Radiology 5/2013 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.